AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
With a market cap of 368.38B, AbbVie(ABBV) trades at $208.00. The stock has a price-to-earnings ratio of 102.52 and currently yields dividends of 3.2%.
On 2026-05-14, AbbVie(ABBV) stock moved within a range of $204.30 to $209.53. With shares now at $208.00, the stock is trading +1.8% above its intraday low and -0.7% below the session's peak.
Trading activity shows a volume of 5.53M, compared to an average daily volume of 6.23M.
The stock's 52-week range extends from a low of $176.57 to a high of $244.81.
The stock's 52-week range extends from a low of $176.57 to a high of $244.81.
ABBV News
Advertisement What AbbVie’s Recent Performance Tells You AbbVie (ABBV) has drawn investor attention after a mixed recent run in the stock. The share price is...
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Key Points AbbVie's Skyrizi is one of its most important growth drivers. This drug could face competition from a newer medicine under development that appears...
Analyst ratings
74%
of 34 ratingsMore ABBV News
AbbVie ( (ABBV) ) has been popular among investors this week. Here is a recap of the key news on this stock. Unlock hedge fund-level data and powerful investin...
AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected r...
Investors may be wondering if AbbVie at around US$202 a share still offers value, or if most of the opportunity has already played out. The stock has recently...
In late April and early May 2026, AbbVie reported first‑quarter revenue of US$15.00 billion alongside a year-on-year drop in net income to US$695 million, while...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.